+ Watch REGN
on My Watchlist
The Company is a biopharmaceutical company that discovers, develops, and intends to commercialize pharmaceutical products for the treatment of serious medical conditions.
Very simply, I don't see Eylea being worth this much. Sure the data has shown its more effective than Avastin, but a $6.6 billion price tag and even in a utopian view maybe 10 times 2012 sales just seems unrealisitc. Arcalyst sales are flat and expenses are rising in part because of Eylea. This company is priced for perfection and all the shareholders are counting their chickens.... but I've yet to see a single egg hatch yet. TMFUltraLong
http://www.bloomberg.com/news/2011-09-21/va-drops-roche-s-avastin-for-eye-disease-citing-infection-risks.htmlLooks like Avastin's rival is being dropped by the Department of Veterans.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions